nodes	percent_of_prediction	percent_of_DWPC	metapath
Naltrexone—ABCB1—esophageal cancer	0.643	1	CbGaD
Naltrexone—Naloxone—TLR4—esophageal cancer	0.00444	0.525	CrCbGaD
Naltrexone—Buprenorphine—CYP2A6—esophageal cancer	0.00143	0.169	CrCbGaD
Naltrexone—Dysphonia—Capecitabine—esophageal cancer	0.00125	0.0055	CcSEcCtD
Naltrexone—Phlebitis—Cisplatin—esophageal cancer	0.00118	0.00517	CcSEcCtD
Naltrexone—Chest discomfort—Capecitabine—esophageal cancer	0.00116	0.00512	CcSEcCtD
Naltrexone—Musculoskeletal stiffness—Capecitabine—esophageal cancer	0.00115	0.00505	CcSEcCtD
Naltrexone—Gastrooesophageal reflux disease—Capecitabine—esophageal cancer	0.00114	0.00501	CcSEcCtD
Naltrexone—Cellulitis—Capecitabine—esophageal cancer	0.00113	0.00498	CcSEcCtD
Naltrexone—Oropharyngeal pain—Capecitabine—esophageal cancer	0.00113	0.00498	CcSEcCtD
Naltrexone—Cardiac failure congestive—Cisplatin—esophageal cancer	0.00112	0.00492	CcSEcCtD
Naltrexone—Nasal congestion—Cisplatin—esophageal cancer	0.00111	0.00489	CcSEcCtD
Naltrexone—Ulcer—Capecitabine—esophageal cancer	0.00109	0.00479	CcSEcCtD
Naltrexone—Hydromorphone—PTGS1—esophageal cancer	0.00108	0.128	CrCbGaD
Naltrexone—Pulmonary embolism—Capecitabine—esophageal cancer	0.00103	0.00453	CcSEcCtD
Naltrexone—Blood pressure increased—Capecitabine—esophageal cancer	0.00103	0.00453	CcSEcCtD
Naltrexone—Injection site reaction—Capecitabine—esophageal cancer	0.00102	0.0045	CcSEcCtD
Naltrexone—Gastrointestinal haemorrhage—Cisplatin—esophageal cancer	0.00101	0.00446	CcSEcCtD
Naltrexone—Hepatotoxicity—Methotrexate—esophageal cancer	0.000991	0.00436	CcSEcCtD
Naltrexone—Colitis—Capecitabine—esophageal cancer	0.000987	0.00435	CcSEcCtD
Naltrexone—Face oedema—Cisplatin—esophageal cancer	0.000978	0.0043	CcSEcCtD
Naltrexone—Irritability—Cisplatin—esophageal cancer	0.000967	0.00426	CcSEcCtD
Naltrexone—Dehydration—Cisplatin—esophageal cancer	0.000942	0.00415	CcSEcCtD
Naltrexone—Aspartate aminotransferase increased—Cisplatin—esophageal cancer	0.000912	0.00401	CcSEcCtD
Naltrexone—Cramp muscle—Cisplatin—esophageal cancer	0.000912	0.00401	CcSEcCtD
Naltrexone—Nasopharyngitis—Cisplatin—esophageal cancer	0.000906	0.00399	CcSEcCtD
Naltrexone—Mental disability—Capecitabine—esophageal cancer	0.000892	0.00393	CcSEcCtD
Naltrexone—Phlebitis—Capecitabine—esophageal cancer	0.000867	0.00381	CcSEcCtD
Naltrexone—Sleep disorder—Capecitabine—esophageal cancer	0.000862	0.0038	CcSEcCtD
Naltrexone—Musculoskeletal stiffness—Methotrexate—esophageal cancer	0.000853	0.00376	CcSEcCtD
Naltrexone—Sweating increased—Cisplatin—esophageal cancer	0.000853	0.00375	CcSEcCtD
Naltrexone—Swelling—Capecitabine—esophageal cancer	0.000846	0.00373	CcSEcCtD
Naltrexone—Gastroenteritis—Capecitabine—esophageal cancer	0.000842	0.00371	CcSEcCtD
Naltrexone—Abdominal discomfort—Cisplatin—esophageal cancer	0.000839	0.00369	CcSEcCtD
Naltrexone—Ulcer—Methotrexate—esophageal cancer	0.000809	0.00356	CcSEcCtD
Naltrexone—Hepatic enzyme increased—Methotrexate—esophageal cancer	0.000809	0.00356	CcSEcCtD
Naltrexone—Libido decreased—Capecitabine—esophageal cancer	0.000805	0.00354	CcSEcCtD
Naltrexone—Hot flush—Capecitabine—esophageal cancer	0.000798	0.00351	CcSEcCtD
Naltrexone—Increased appetite—Capecitabine—esophageal cancer	0.000795	0.0035	CcSEcCtD
Naltrexone—Menopausal symptoms—Capecitabine—esophageal cancer	0.000791	0.00348	CcSEcCtD
Naltrexone—Atrial fibrillation—Capecitabine—esophageal cancer	0.000788	0.00347	CcSEcCtD
Naltrexone—Thirst—Capecitabine—esophageal cancer	0.000784	0.00345	CcSEcCtD
Naltrexone—Purpura—Capecitabine—esophageal cancer	0.000775	0.00341	CcSEcCtD
Naltrexone—Acute coronary syndrome—Cisplatin—esophageal cancer	0.000769	0.00339	CcSEcCtD
Naltrexone—Arthritis—Capecitabine—esophageal cancer	0.000768	0.00338	CcSEcCtD
Naltrexone—Pulmonary embolism—Methotrexate—esophageal cancer	0.000766	0.00337	CcSEcCtD
Naltrexone—Myocardial infarction—Cisplatin—esophageal cancer	0.000765	0.00337	CcSEcCtD
Naltrexone—Lethargy—Capecitabine—esophageal cancer	0.000762	0.00335	CcSEcCtD
Naltrexone—Conjunctivitis—Cisplatin—esophageal cancer	0.000759	0.00334	CcSEcCtD
Naltrexone—Gastrointestinal haemorrhage—Capecitabine—esophageal cancer	0.000747	0.00329	CcSEcCtD
Naltrexone—Pain in extremity—Capecitabine—esophageal cancer	0.000747	0.00329	CcSEcCtD
Naltrexone—Disturbance in sexual arousal—Capecitabine—esophageal cancer	0.000741	0.00326	CcSEcCtD
Naltrexone—Hepatobiliary disease—Cisplatin—esophageal cancer	0.000738	0.00325	CcSEcCtD
Naltrexone—Migraine—Capecitabine—esophageal cancer	0.000735	0.00323	CcSEcCtD
Naltrexone—Face oedema—Capecitabine—esophageal cancer	0.000721	0.00317	CcSEcCtD
Naltrexone—Irritability—Capecitabine—esophageal cancer	0.000713	0.00314	CcSEcCtD
Naltrexone—Dehydration—Capecitabine—esophageal cancer	0.000694	0.00306	CcSEcCtD
Naltrexone—Connective tissue disorder—Cisplatin—esophageal cancer	0.000688	0.00303	CcSEcCtD
Naltrexone—Abdominal pain upper—Capecitabine—esophageal cancer	0.000682	0.003	CcSEcCtD
Naltrexone—Aspartate aminotransferase increased—Capecitabine—esophageal cancer	0.000672	0.00296	CcSEcCtD
Naltrexone—Nasopharyngitis—Capecitabine—esophageal cancer	0.000668	0.00294	CcSEcCtD
Naltrexone—Alanine aminotransferase increased—Capecitabine—esophageal cancer	0.000658	0.0029	CcSEcCtD
Naltrexone—Eye disorder—Cisplatin—esophageal cancer	0.000655	0.00288	CcSEcCtD
Naltrexone—Tinnitus—Cisplatin—esophageal cancer	0.000653	0.00288	CcSEcCtD
Naltrexone—Lymphadenopathy—Methotrexate—esophageal cancer	0.000651	0.00287	CcSEcCtD
Naltrexone—Cardiac disorder—Cisplatin—esophageal cancer	0.00065	0.00286	CcSEcCtD
Naltrexone—Influenza—Capecitabine—esophageal cancer	0.000645	0.00284	CcSEcCtD
Naltrexone—Immune system disorder—Cisplatin—esophageal cancer	0.000633	0.00279	CcSEcCtD
Naltrexone—Mediastinal disorder—Cisplatin—esophageal cancer	0.000631	0.00278	CcSEcCtD
Naltrexone—Angina pectoris—Capecitabine—esophageal cancer	0.000629	0.00277	CcSEcCtD
Naltrexone—Sweating increased—Capecitabine—esophageal cancer	0.000629	0.00277	CcSEcCtD
Naltrexone—Bronchitis—Capecitabine—esophageal cancer	0.000621	0.00273	CcSEcCtD
Naltrexone—Alopecia—Cisplatin—esophageal cancer	0.000619	0.00273	CcSEcCtD
Naltrexone—Abdominal discomfort—Capecitabine—esophageal cancer	0.000619	0.00272	CcSEcCtD
Naltrexone—Malnutrition—Cisplatin—esophageal cancer	0.00061	0.00268	CcSEcCtD
Naltrexone—Flatulence—Cisplatin—esophageal cancer	0.000601	0.00265	CcSEcCtD
Naltrexone—Upper respiratory tract infection—Capecitabine—esophageal cancer	0.0006	0.00264	CcSEcCtD
Naltrexone—Weight increased—Capecitabine—esophageal cancer	0.000587	0.00258	CcSEcCtD
Naltrexone—Muscle spasms—Cisplatin—esophageal cancer	0.000586	0.00258	CcSEcCtD
Naltrexone—Weight decreased—Capecitabine—esophageal cancer	0.000584	0.00257	CcSEcCtD
Naltrexone—Pneumonia—Capecitabine—esophageal cancer	0.000579	0.00255	CcSEcCtD
Naltrexone—Infestation NOS—Capecitabine—esophageal cancer	0.000575	0.00253	CcSEcCtD
Naltrexone—Infestation—Capecitabine—esophageal cancer	0.000575	0.00253	CcSEcCtD
Naltrexone—Vision blurred—Cisplatin—esophageal cancer	0.000575	0.00253	CcSEcCtD
Naltrexone—Depression—Capecitabine—esophageal cancer	0.000574	0.00253	CcSEcCtD
Naltrexone—Tremor—Cisplatin—esophageal cancer	0.000571	0.00252	CcSEcCtD
Naltrexone—Acute coronary syndrome—Capecitabine—esophageal cancer	0.000567	0.0025	CcSEcCtD
Naltrexone—Lethargy—Methotrexate—esophageal cancer	0.000567	0.0025	CcSEcCtD
Naltrexone—Ill-defined disorder—Cisplatin—esophageal cancer	0.000566	0.00249	CcSEcCtD
Naltrexone—Myocardial infarction—Capecitabine—esophageal cancer	0.000564	0.00248	CcSEcCtD
Naltrexone—Urinary tract infection—Capecitabine—esophageal cancer	0.000559	0.00246	CcSEcCtD
Naltrexone—Conjunctivitis—Capecitabine—esophageal cancer	0.000559	0.00246	CcSEcCtD
Naltrexone—Malaise—Cisplatin—esophageal cancer	0.00055	0.00242	CcSEcCtD
Naltrexone—Hepatobiliary disease—Capecitabine—esophageal cancer	0.000544	0.0024	CcSEcCtD
Naltrexone—Epistaxis—Capecitabine—esophageal cancer	0.000543	0.00239	CcSEcCtD
Naltrexone—Buprenorphine—ABCB1—esophageal cancer	0.000533	0.063	CrCbGaD
Naltrexone—Irritability—Methotrexate—esophageal cancer	0.00053	0.00233	CcSEcCtD
Naltrexone—Naloxone—ABCB1—esophageal cancer	0.000529	0.0625	CrCbGaD
Naltrexone—Convulsion—Cisplatin—esophageal cancer	0.000528	0.00233	CcSEcCtD
Naltrexone—Myalgia—Cisplatin—esophageal cancer	0.000519	0.00229	CcSEcCtD
Naltrexone—Anxiety—Cisplatin—esophageal cancer	0.000517	0.00228	CcSEcCtD
Naltrexone—Hepatitis—Capecitabine—esophageal cancer	0.000516	0.00227	CcSEcCtD
Naltrexone—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—esophageal cancer	0.000516	0.00227	CcSEcCtD
Naltrexone—Discomfort—Cisplatin—esophageal cancer	0.000513	0.00226	CcSEcCtD
Naltrexone—Pharyngitis—Capecitabine—esophageal cancer	0.000513	0.00226	CcSEcCtD
Naltrexone—Connective tissue disorder—Capecitabine—esophageal cancer	0.000508	0.00223	CcSEcCtD
Naltrexone—Anaphylactic shock—Cisplatin—esophageal cancer	0.000498	0.00219	CcSEcCtD
Naltrexone—Oedema—Cisplatin—esophageal cancer	0.000498	0.00219	CcSEcCtD
Naltrexone—Infection—Cisplatin—esophageal cancer	0.000495	0.00218	CcSEcCtD
Naltrexone—Nervous system disorder—Cisplatin—esophageal cancer	0.000488	0.00215	CcSEcCtD
Naltrexone—Tachycardia—Cisplatin—esophageal cancer	0.000486	0.00214	CcSEcCtD
Naltrexone—Skin disorder—Cisplatin—esophageal cancer	0.000483	0.00213	CcSEcCtD
Naltrexone—Eye disorder—Capecitabine—esophageal cancer	0.000483	0.00212	CcSEcCtD
Naltrexone—Tinnitus—Capecitabine—esophageal cancer	0.000482	0.00212	CcSEcCtD
Naltrexone—Hyperhidrosis—Cisplatin—esophageal cancer	0.000481	0.00212	CcSEcCtD
Naltrexone—Cardiac disorder—Capecitabine—esophageal cancer	0.000479	0.00211	CcSEcCtD
Naltrexone—Anorexia—Cisplatin—esophageal cancer	0.000474	0.00209	CcSEcCtD
Naltrexone—Angiopathy—Capecitabine—esophageal cancer	0.000469	0.00206	CcSEcCtD
Naltrexone—Immune system disorder—Capecitabine—esophageal cancer	0.000466	0.00205	CcSEcCtD
Naltrexone—Mediastinal disorder—Capecitabine—esophageal cancer	0.000465	0.00205	CcSEcCtD
Naltrexone—Chills—Capecitabine—esophageal cancer	0.000463	0.00204	CcSEcCtD
Naltrexone—Abdominal discomfort—Methotrexate—esophageal cancer	0.00046	0.00203	CcSEcCtD
Naltrexone—Alopecia—Capecitabine—esophageal cancer	0.000456	0.00201	CcSEcCtD
Naltrexone—Musculoskeletal discomfort—Cisplatin—esophageal cancer	0.000454	0.002	CcSEcCtD
Naltrexone—Mental disorder—Capecitabine—esophageal cancer	0.000452	0.00199	CcSEcCtD
Naltrexone—Malnutrition—Capecitabine—esophageal cancer	0.00045	0.00198	CcSEcCtD
Naltrexone—Paraesthesia—Cisplatin—esophageal cancer	0.000447	0.00197	CcSEcCtD
Naltrexone—Morphine—ABCB1—esophageal cancer	0.000447	0.0528	CrCbGaD
Naltrexone—Upper respiratory tract infection—Methotrexate—esophageal cancer	0.000446	0.00197	CcSEcCtD
Naltrexone—Dyspnoea—Cisplatin—esophageal cancer	0.000444	0.00195	CcSEcCtD
Naltrexone—Flatulence—Capecitabine—esophageal cancer	0.000443	0.00195	CcSEcCtD
Naltrexone—Dysgeusia—Capecitabine—esophageal cancer	0.00044	0.00194	CcSEcCtD
Naltrexone—Back pain—Capecitabine—esophageal cancer	0.000435	0.00191	CcSEcCtD
Naltrexone—Decreased appetite—Cisplatin—esophageal cancer	0.000433	0.0019	CcSEcCtD
Naltrexone—Muscle spasms—Capecitabine—esophageal cancer	0.000432	0.0019	CcSEcCtD
Naltrexone—Pneumonia—Methotrexate—esophageal cancer	0.000431	0.0019	CcSEcCtD
Naltrexone—Gastrointestinal disorder—Cisplatin—esophageal cancer	0.00043	0.00189	CcSEcCtD
Naltrexone—Infestation NOS—Methotrexate—esophageal cancer	0.000428	0.00189	CcSEcCtD
Naltrexone—Infestation—Methotrexate—esophageal cancer	0.000428	0.00189	CcSEcCtD
Naltrexone—Depression—Methotrexate—esophageal cancer	0.000427	0.00188	CcSEcCtD
Naltrexone—Pain—Cisplatin—esophageal cancer	0.000426	0.00187	CcSEcCtD
Naltrexone—Vision blurred—Capecitabine—esophageal cancer	0.000424	0.00187	CcSEcCtD
Naltrexone—Tremor—Capecitabine—esophageal cancer	0.000421	0.00185	CcSEcCtD
Naltrexone—Ill-defined disorder—Capecitabine—esophageal cancer	0.000417	0.00184	CcSEcCtD
Naltrexone—Conjunctivitis—Methotrexate—esophageal cancer	0.000416	0.00183	CcSEcCtD
Naltrexone—Feeling abnormal—Cisplatin—esophageal cancer	0.00041	0.00181	CcSEcCtD
Naltrexone—Malaise—Capecitabine—esophageal cancer	0.000405	0.00178	CcSEcCtD
Naltrexone—Hepatobiliary disease—Methotrexate—esophageal cancer	0.000405	0.00178	CcSEcCtD
Naltrexone—Epistaxis—Methotrexate—esophageal cancer	0.000404	0.00178	CcSEcCtD
Naltrexone—Syncope—Capecitabine—esophageal cancer	0.000403	0.00177	CcSEcCtD
Naltrexone—Palpitations—Capecitabine—esophageal cancer	0.000397	0.00175	CcSEcCtD
Naltrexone—Loss of consciousness—Capecitabine—esophageal cancer	0.000395	0.00174	CcSEcCtD
Naltrexone—Body temperature increased—Cisplatin—esophageal cancer	0.000393	0.00173	CcSEcCtD
Naltrexone—Cough—Capecitabine—esophageal cancer	0.000392	0.00173	CcSEcCtD
Naltrexone—Hypertension—Capecitabine—esophageal cancer	0.000388	0.00171	CcSEcCtD
Naltrexone—Hepatitis—Methotrexate—esophageal cancer	0.000384	0.00169	CcSEcCtD
Naltrexone—Chest pain—Capecitabine—esophageal cancer	0.000383	0.00168	CcSEcCtD
Naltrexone—Myalgia—Capecitabine—esophageal cancer	0.000383	0.00168	CcSEcCtD
Naltrexone—Arthralgia—Capecitabine—esophageal cancer	0.000383	0.00168	CcSEcCtD
Naltrexone—Pharyngitis—Methotrexate—esophageal cancer	0.000382	0.00168	CcSEcCtD
Naltrexone—Anxiety—Capecitabine—esophageal cancer	0.000381	0.00168	CcSEcCtD
Naltrexone—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—esophageal cancer	0.00038	0.00167	CcSEcCtD
Naltrexone—Discomfort—Capecitabine—esophageal cancer	0.000378	0.00166	CcSEcCtD
Naltrexone—Dry mouth—Capecitabine—esophageal cancer	0.000374	0.00165	CcSEcCtD
Naltrexone—Confusional state—Capecitabine—esophageal cancer	0.00037	0.00163	CcSEcCtD
Naltrexone—Oedema—Capecitabine—esophageal cancer	0.000367	0.00162	CcSEcCtD
Naltrexone—Hypersensitivity—Cisplatin—esophageal cancer	0.000367	0.00161	CcSEcCtD
Naltrexone—Infection—Capecitabine—esophageal cancer	0.000365	0.0016	CcSEcCtD
Naltrexone—Shock—Capecitabine—esophageal cancer	0.000361	0.00159	CcSEcCtD
Naltrexone—Nervous system disorder—Capecitabine—esophageal cancer	0.00036	0.00158	CcSEcCtD
Naltrexone—Eye disorder—Methotrexate—esophageal cancer	0.000359	0.00158	CcSEcCtD
Naltrexone—Tinnitus—Methotrexate—esophageal cancer	0.000358	0.00158	CcSEcCtD
Naltrexone—Tachycardia—Capecitabine—esophageal cancer	0.000358	0.00158	CcSEcCtD
Naltrexone—Asthenia—Cisplatin—esophageal cancer	0.000357	0.00157	CcSEcCtD
Naltrexone—Cardiac disorder—Methotrexate—esophageal cancer	0.000357	0.00157	CcSEcCtD
Naltrexone—Skin disorder—Capecitabine—esophageal cancer	0.000356	0.00157	CcSEcCtD
Naltrexone—Hyperhidrosis—Capecitabine—esophageal cancer	0.000355	0.00156	CcSEcCtD
Naltrexone—Anorexia—Capecitabine—esophageal cancer	0.00035	0.00154	CcSEcCtD
Naltrexone—Angiopathy—Methotrexate—esophageal cancer	0.000349	0.00154	CcSEcCtD
Naltrexone—Immune system disorder—Methotrexate—esophageal cancer	0.000347	0.00153	CcSEcCtD
Naltrexone—Mediastinal disorder—Methotrexate—esophageal cancer	0.000346	0.00153	CcSEcCtD
Naltrexone—Chills—Methotrexate—esophageal cancer	0.000345	0.00152	CcSEcCtD
Naltrexone—Diarrhoea—Cisplatin—esophageal cancer	0.000341	0.0015	CcSEcCtD
Naltrexone—Alopecia—Methotrexate—esophageal cancer	0.00034	0.0015	CcSEcCtD
Naltrexone—Mental disorder—Methotrexate—esophageal cancer	0.000337	0.00148	CcSEcCtD
Naltrexone—Malnutrition—Methotrexate—esophageal cancer	0.000335	0.00147	CcSEcCtD
Naltrexone—Musculoskeletal discomfort—Capecitabine—esophageal cancer	0.000334	0.00147	CcSEcCtD
Naltrexone—Insomnia—Capecitabine—esophageal cancer	0.000332	0.00146	CcSEcCtD
Naltrexone—Paraesthesia—Capecitabine—esophageal cancer	0.000329	0.00145	CcSEcCtD
Naltrexone—Dysgeusia—Methotrexate—esophageal cancer	0.000328	0.00144	CcSEcCtD
Naltrexone—Dyspnoea—Capecitabine—esophageal cancer	0.000327	0.00144	CcSEcCtD
Naltrexone—Back pain—Methotrexate—esophageal cancer	0.000324	0.00143	CcSEcCtD
Naltrexone—Decreased appetite—Capecitabine—esophageal cancer	0.000319	0.0014	CcSEcCtD
Naltrexone—Gastrointestinal disorder—Capecitabine—esophageal cancer	0.000317	0.00139	CcSEcCtD
Naltrexone—Vomiting—Cisplatin—esophageal cancer	0.000316	0.00139	CcSEcCtD
Naltrexone—Fatigue—Capecitabine—esophageal cancer	0.000316	0.00139	CcSEcCtD
Naltrexone—Vision blurred—Methotrexate—esophageal cancer	0.000315	0.00139	CcSEcCtD
Naltrexone—Rash—Cisplatin—esophageal cancer	0.000314	0.00138	CcSEcCtD
Naltrexone—Pain—Capecitabine—esophageal cancer	0.000314	0.00138	CcSEcCtD
Naltrexone—Constipation—Capecitabine—esophageal cancer	0.000314	0.00138	CcSEcCtD
Naltrexone—Dermatitis—Cisplatin—esophageal cancer	0.000314	0.00138	CcSEcCtD
Naltrexone—Ill-defined disorder—Methotrexate—esophageal cancer	0.000311	0.00137	CcSEcCtD
Naltrexone—Feeling abnormal—Capecitabine—esophageal cancer	0.000302	0.00133	CcSEcCtD
Naltrexone—Malaise—Methotrexate—esophageal cancer	0.000302	0.00133	CcSEcCtD
Naltrexone—Gastrointestinal pain—Capecitabine—esophageal cancer	0.0003	0.00132	CcSEcCtD
Naltrexone—Nausea—Cisplatin—esophageal cancer	0.000296	0.0013	CcSEcCtD
Naltrexone—Cough—Methotrexate—esophageal cancer	0.000292	0.00129	CcSEcCtD
Naltrexone—Urticaria—Capecitabine—esophageal cancer	0.000291	0.00128	CcSEcCtD
Naltrexone—Abdominal pain—Capecitabine—esophageal cancer	0.00029	0.00128	CcSEcCtD
Naltrexone—Body temperature increased—Capecitabine—esophageal cancer	0.00029	0.00128	CcSEcCtD
Naltrexone—Convulsion—Methotrexate—esophageal cancer	0.00029	0.00128	CcSEcCtD
Naltrexone—Myalgia—Methotrexate—esophageal cancer	0.000285	0.00125	CcSEcCtD
Naltrexone—Chest pain—Methotrexate—esophageal cancer	0.000285	0.00125	CcSEcCtD
Naltrexone—Arthralgia—Methotrexate—esophageal cancer	0.000285	0.00125	CcSEcCtD
Naltrexone—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—esophageal cancer	0.000283	0.00125	CcSEcCtD
Naltrexone—Discomfort—Methotrexate—esophageal cancer	0.000282	0.00124	CcSEcCtD
Naltrexone—Confusional state—Methotrexate—esophageal cancer	0.000275	0.00121	CcSEcCtD
Naltrexone—Anaphylactic shock—Methotrexate—esophageal cancer	0.000273	0.0012	CcSEcCtD
Naltrexone—Infection—Methotrexate—esophageal cancer	0.000271	0.00119	CcSEcCtD
Naltrexone—Hypersensitivity—Capecitabine—esophageal cancer	0.00027	0.00119	CcSEcCtD
Naltrexone—Nervous system disorder—Methotrexate—esophageal cancer	0.000268	0.00118	CcSEcCtD
Naltrexone—Skin disorder—Methotrexate—esophageal cancer	0.000265	0.00117	CcSEcCtD
Naltrexone—Hyperhidrosis—Methotrexate—esophageal cancer	0.000264	0.00116	CcSEcCtD
Naltrexone—Asthenia—Capecitabine—esophageal cancer	0.000263	0.00116	CcSEcCtD
Naltrexone—Anorexia—Methotrexate—esophageal cancer	0.00026	0.00115	CcSEcCtD
Naltrexone—Pruritus—Capecitabine—esophageal cancer	0.00026	0.00114	CcSEcCtD
Naltrexone—Diarrhoea—Capecitabine—esophageal cancer	0.000251	0.00111	CcSEcCtD
Naltrexone—Musculoskeletal discomfort—Methotrexate—esophageal cancer	0.000249	0.0011	CcSEcCtD
Naltrexone—Insomnia—Methotrexate—esophageal cancer	0.000247	0.00109	CcSEcCtD
Naltrexone—Paraesthesia—Methotrexate—esophageal cancer	0.000245	0.00108	CcSEcCtD
Naltrexone—Dyspnoea—Methotrexate—esophageal cancer	0.000244	0.00107	CcSEcCtD
Naltrexone—Somnolence—Methotrexate—esophageal cancer	0.000243	0.00107	CcSEcCtD
Naltrexone—Dizziness—Capecitabine—esophageal cancer	0.000243	0.00107	CcSEcCtD
Naltrexone—Decreased appetite—Methotrexate—esophageal cancer	0.000237	0.00105	CcSEcCtD
Naltrexone—Gastrointestinal disorder—Methotrexate—esophageal cancer	0.000236	0.00104	CcSEcCtD
Naltrexone—Fatigue—Methotrexate—esophageal cancer	0.000235	0.00104	CcSEcCtD
Naltrexone—Pain—Methotrexate—esophageal cancer	0.000234	0.00103	CcSEcCtD
Naltrexone—Vomiting—Capecitabine—esophageal cancer	0.000233	0.00103	CcSEcCtD
Naltrexone—Rash—Capecitabine—esophageal cancer	0.000231	0.00102	CcSEcCtD
Naltrexone—Dermatitis—Capecitabine—esophageal cancer	0.000231	0.00102	CcSEcCtD
Naltrexone—Headache—Capecitabine—esophageal cancer	0.00023	0.00101	CcSEcCtD
Naltrexone—Feeling abnormal—Methotrexate—esophageal cancer	0.000225	0.000991	CcSEcCtD
Naltrexone—Gastrointestinal pain—Methotrexate—esophageal cancer	0.000223	0.000983	CcSEcCtD
Naltrexone—Nausea—Capecitabine—esophageal cancer	0.000218	0.000959	CcSEcCtD
Naltrexone—Urticaria—Methotrexate—esophageal cancer	0.000217	0.000955	CcSEcCtD
Naltrexone—Abdominal pain—Methotrexate—esophageal cancer	0.000216	0.00095	CcSEcCtD
Naltrexone—Body temperature increased—Methotrexate—esophageal cancer	0.000216	0.00095	CcSEcCtD
Naltrexone—Hypersensitivity—Methotrexate—esophageal cancer	0.000201	0.000886	CcSEcCtD
Naltrexone—Asthenia—Methotrexate—esophageal cancer	0.000196	0.000863	CcSEcCtD
Naltrexone—Pruritus—Methotrexate—esophageal cancer	0.000193	0.000851	CcSEcCtD
Naltrexone—Diarrhoea—Methotrexate—esophageal cancer	0.000187	0.000823	CcSEcCtD
Naltrexone—Dizziness—Methotrexate—esophageal cancer	0.000181	0.000795	CcSEcCtD
Naltrexone—Vomiting—Methotrexate—esophageal cancer	0.000174	0.000764	CcSEcCtD
Naltrexone—Rash—Methotrexate—esophageal cancer	0.000172	0.000758	CcSEcCtD
Naltrexone—Dermatitis—Methotrexate—esophageal cancer	0.000172	0.000757	CcSEcCtD
Naltrexone—Headache—Methotrexate—esophageal cancer	0.000171	0.000753	CcSEcCtD
Naltrexone—Nausea—Methotrexate—esophageal cancer	0.000162	0.000714	CcSEcCtD
Naltrexone—ABCB1—Allograft Rejection—CASP8—esophageal cancer	0.00015	0.00123	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—KMT2D—esophageal cancer	0.000148	0.00122	CbGpPWpGaD
Naltrexone—OPRK1—GPCR downstream signaling—PDE4D—esophageal cancer	0.000144	0.00119	CbGpPWpGaD
Naltrexone—OPRK1—Signaling by GPCR—AKAP13—esophageal cancer	0.000143	0.00118	CbGpPWpGaD
Naltrexone—OPRD1—Signaling by GPCR—GNG7—esophageal cancer	0.000142	0.00117	CbGpPWpGaD
Naltrexone—ABCB1—Integrated Pancreatic Cancer Pathway—BUB1B—esophageal cancer	0.000141	0.00116	CbGpPWpGaD
Naltrexone—OPRD1—GPCR downstream signaling—CXCL2—esophageal cancer	0.000138	0.00114	CbGpPWpGaD
Naltrexone—OPRK1—GPCR downstream signaling—GNG7—esophageal cancer	0.000137	0.00113	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—WWOX—esophageal cancer	0.000137	0.00113	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—SLC10A2—esophageal cancer	0.000136	0.00112	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—CA1—esophageal cancer	0.000136	0.00112	CbGpPWpGaD
Naltrexone—ABCB1—Integrated Pancreatic Cancer Pathway—CHEK2—esophageal cancer	0.000134	0.0011	CbGpPWpGaD
Naltrexone—OPRM1—GPCR downstream signaling—AKAP13—esophageal cancer	0.000133	0.0011	CbGpPWpGaD
Naltrexone—ABCB1—Transmembrane transport of small molecules—SLC10A2—esophageal cancer	0.000133	0.0011	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—ADCYAP1—esophageal cancer	0.000131	0.00108	CbGpPWpGaD
Naltrexone—OPRK1—Signaling by GPCR—PDE4D—esophageal cancer	0.000131	0.00108	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—FKBP1A—esophageal cancer	0.00013	0.00108	CbGpPWpGaD
Naltrexone—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—MYC—esophageal cancer	0.000129	0.00107	CbGpPWpGaD
Naltrexone—OPRD1—GPCR downstream signaling—ANXA1—esophageal cancer	0.000128	0.00106	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—WIF1—esophageal cancer	0.000127	0.00105	CbGpPWpGaD
Naltrexone—OPRD1—Signaling by GPCR—CXCL2—esophageal cancer	0.000125	0.00103	CbGpPWpGaD
Naltrexone—ABCB1—Transmembrane transport of small molecules—ATP1B2—esophageal cancer	0.000125	0.00103	CbGpPWpGaD
Naltrexone—OPRD1—GPCR downstream signaling—SST—esophageal cancer	0.000125	0.00103	CbGpPWpGaD
Naltrexone—OPRK1—Signaling by GPCR—GNG7—esophageal cancer	0.000125	0.00103	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—KMT2D—esophageal cancer	0.000125	0.00103	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—CA2—esophageal cancer	0.000124	0.00102	CbGpPWpGaD
Naltrexone—OPRM1—GPCR downstream signaling—PDE4D—esophageal cancer	0.000122	0.00101	CbGpPWpGaD
Naltrexone—OPRD1—GPCR downstream signaling—GHRL—esophageal cancer	0.000122	0.001	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—AKAP13—esophageal cancer	0.000121	0.000999	CbGpPWpGaD
Naltrexone—OPRK1—GPCR downstream signaling—CXCL2—esophageal cancer	0.000121	0.000998	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—WWOX—esophageal cancer	0.00012	0.000991	CbGpPWpGaD
Naltrexone—ABCB1—Transmembrane transport of small molecules—SLC39A6—esophageal cancer	0.000119	0.000978	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—CSNK1A1—esophageal cancer	0.000118	0.00097	CbGpPWpGaD
Naltrexone—ABCB1—HIF-1-alpha transcription factor network—EP300—esophageal cancer	0.000117	0.000965	CbGpPWpGaD
Naltrexone—OPRD1—Signaling by GPCR—ANXA1—esophageal cancer	0.000117	0.000961	CbGpPWpGaD
Naltrexone—OPRM1—GPCR downstream signaling—GNG7—esophageal cancer	0.000116	0.000957	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—PLCE1—esophageal cancer	0.000116	0.000952	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—ADH7—esophageal cancer	0.000116	0.000952	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—FKBP1A—esophageal cancer	0.000114	0.000943	CbGpPWpGaD
Naltrexone—ABCB1—Integrated Pancreatic Cancer Pathway—ABL1—esophageal cancer	0.000113	0.000935	CbGpPWpGaD
Naltrexone—OPRD1—Signaling by GPCR—SST—esophageal cancer	0.000113	0.000934	CbGpPWpGaD
Naltrexone—ABCB1—Transmembrane transport of small molecules—AQP3—esophageal cancer	0.000113	0.000933	CbGpPWpGaD
Naltrexone—OPRK1—GPCR downstream signaling—ANXA1—esophageal cancer	0.000113	0.000928	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—WIF1—esophageal cancer	0.000112	0.000921	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—ADCYAP1—esophageal cancer	0.000111	0.000916	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—PDE4D—esophageal cancer	0.000111	0.000914	CbGpPWpGaD
Naltrexone—OPRD1—Signaling by GPCR—GHRL—esophageal cancer	0.00011	0.000911	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—PFN1—esophageal cancer	0.00011	0.000907	CbGpPWpGaD
Naltrexone—OPRK1—Signaling by GPCR—CXCL2—esophageal cancer	0.00011	0.000906	CbGpPWpGaD
Naltrexone—ABCB1—Integrated Pancreatic Cancer Pathway—SMAD4—esophageal cancer	0.00011	0.000906	CbGpPWpGaD
Naltrexone—OPRK1—GPCR downstream signaling—SST—esophageal cancer	0.000109	0.000902	CbGpPWpGaD
Naltrexone—ABCB1—Transmembrane transport of small molecules—ATP4A—esophageal cancer	0.000109	0.000894	CbGpPWpGaD
Naltrexone—ABCB1—Transmembrane transport of small molecules—SLC30A7—esophageal cancer	0.000109	0.000894	CbGpPWpGaD
Naltrexone—OPRK1—GPCR downstream signaling—GHRL—esophageal cancer	0.000107	0.000879	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—GNG7—esophageal cancer	0.000105	0.000869	CbGpPWpGaD
Naltrexone—ABCB1—Integrated Pancreatic Cancer Pathway—BAX—esophageal cancer	0.000104	0.000857	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—CSNK1A1—esophageal cancer	0.000103	0.00085	CbGpPWpGaD
Naltrexone—OPRM1—GPCR downstream signaling—CXCL2—esophageal cancer	0.000102	0.000843	CbGpPWpGaD
Naltrexone—OPRK1—Signaling by GPCR—ANXA1—esophageal cancer	0.000102	0.000842	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—WWOX—esophageal cancer	0.000102	0.000838	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—ADH1B—esophageal cancer	0.000101	0.000835	CbGpPWpGaD
Naltrexone—OPRK1—Signaling by GPCR—SST—esophageal cancer	9.94e-05	0.000819	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—ELMO1—esophageal cancer	9.89e-05	0.000815	CbGpPWpGaD
Naltrexone—OPRK1—Signaling by GPCR—GHRL—esophageal cancer	9.69e-05	0.000799	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—TYMP—esophageal cancer	9.68e-05	0.000798	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—FKBP1A—esophageal cancer	9.67e-05	0.000797	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—AKAP13—esophageal cancer	9.66e-05	0.000796	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—PFN1—esophageal cancer	9.65e-05	0.000795	CbGpPWpGaD
Naltrexone—OPRM1—GPCR downstream signaling—ANXA1—esophageal cancer	9.51e-05	0.000784	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—WIF1—esophageal cancer	9.45e-05	0.000779	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—CYP26A1—esophageal cancer	9.42e-05	0.000776	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—CXCL2—esophageal cancer	9.29e-05	0.000766	CbGpPWpGaD
Naltrexone—OPRM1—GPCR downstream signaling—SST—esophageal cancer	9.25e-05	0.000763	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—ALOX15—esophageal cancer	9.18e-05	0.000757	CbGpPWpGaD
Naltrexone—OPRM1—GPCR downstream signaling—GHRL—esophageal cancer	9.02e-05	0.000743	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—HIST1H2BM—esophageal cancer	8.92e-05	0.000735	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—PDE4D—esophageal cancer	8.84e-05	0.000728	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—TPI1—esophageal cancer	8.76e-05	0.000722	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—GSTO1—esophageal cancer	8.76e-05	0.000722	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—CSNK1A1—esophageal cancer	8.72e-05	0.000719	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—ELMO1—esophageal cancer	8.67e-05	0.000714	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—ANXA1—esophageal cancer	8.64e-05	0.000712	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—AKAP13—esophageal cancer	8.47e-05	0.000698	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—GNG7—esophageal cancer	8.41e-05	0.000693	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—SST—esophageal cancer	8.4e-05	0.000693	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—ALDOB—esophageal cancer	8.4e-05	0.000692	CbGpPWpGaD
Naltrexone—ABCB1—Transmembrane transport of small molecules—ABCC2—esophageal cancer	8.22e-05	0.000678	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—GHRL—esophageal cancer	8.19e-05	0.000675	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—PFN1—esophageal cancer	8.16e-05	0.000672	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—GAPDH—esophageal cancer	8.08e-05	0.000666	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—CRABP1—esophageal cancer	8.01e-05	0.00066	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—XIAP—esophageal cancer	7.88e-05	0.000649	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—HIST1H2BM—esophageal cancer	7.82e-05	0.000644	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—PDE4D—esophageal cancer	7.75e-05	0.000639	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—GNG7—esophageal cancer	7.62e-05	0.000628	CbGpPWpGaD
Naltrexone—ABCB1—Transmembrane transport of small molecules—GNG7—esophageal cancer	7.46e-05	0.000615	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—CTNNA1—esophageal cancer	7.45e-05	0.000614	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—CXCL2—esophageal cancer	7.41e-05	0.00061	CbGpPWpGaD
Naltrexone—ABCB1—Integrated Pancreatic Cancer Pathway—CASP8—esophageal cancer	7.38e-05	0.000608	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—GNG7—esophageal cancer	7.37e-05	0.000608	CbGpPWpGaD
Naltrexone—ABCB1—Integrated Pancreatic Cancer Pathway—CREBBP—esophageal cancer	7.35e-05	0.000605	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—BLVRB—esophageal cancer	7.33e-05	0.000604	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—SLC52A3—esophageal cancer	7.33e-05	0.000604	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—ELMO1—esophageal cancer	7.33e-05	0.000604	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—AKAP13—esophageal cancer	7.16e-05	0.00059	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—ALDH2—esophageal cancer	7.14e-05	0.000588	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—PSME2—esophageal cancer	6.92e-05	0.00057	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—PSME1—esophageal cancer	6.92e-05	0.00057	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—XIAP—esophageal cancer	6.91e-05	0.000569	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—ANXA1—esophageal cancer	6.88e-05	0.000567	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—GSTT1—esophageal cancer	6.79e-05	0.00056	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—CYP2A6—esophageal cancer	6.71e-05	0.000553	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—SST—esophageal cancer	6.7e-05	0.000552	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—HIST1H2BM—esophageal cancer	6.61e-05	0.000545	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—PDE4D—esophageal cancer	6.55e-05	0.00054	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—CTNNA1—esophageal cancer	6.53e-05	0.000538	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—GHRL—esophageal cancer	6.53e-05	0.000538	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—NOTCH3—esophageal cancer	6.53e-05	0.000538	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—CXCL2—esophageal cancer	6.49e-05	0.000535	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—FBXW7—esophageal cancer	6.42e-05	0.000529	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—PTGS1—esophageal cancer	6.36e-05	0.000524	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—ENO1—esophageal cancer	6.36e-05	0.000524	CbGpPWpGaD
Naltrexone—ABCB1—Integrated Pancreatic Cancer Pathway—BCL2—esophageal cancer	6.33e-05	0.000522	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—PSME2—esophageal cancer	6.27e-05	0.000517	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—PSME1—esophageal cancer	6.27e-05	0.000517	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—SLC10A2—esophageal cancer	6.23e-05	0.000514	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—CA1—esophageal cancer	6.23e-05	0.000514	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—GNG7—esophageal cancer	6.23e-05	0.000513	CbGpPWpGaD
Naltrexone—ABCB1—Integrated Pancreatic Cancer Pathway—ERBB2—esophageal cancer	6.15e-05	0.000507	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—PSME1—esophageal cancer	6.07e-05	0.0005	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—PSME2—esophageal cancer	6.07e-05	0.0005	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—ANXA1—esophageal cancer	6.04e-05	0.000498	CbGpPWpGaD
Naltrexone—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—esophageal cancer	6.01e-05	0.000496	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—SST—esophageal cancer	5.87e-05	0.000484	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—NOTCH2—esophageal cancer	5.85e-05	0.000483	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—XIAP—esophageal cancer	5.84e-05	0.000481	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—NOTCH3—esophageal cancer	5.72e-05	0.000472	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—GHRL—esophageal cancer	5.72e-05	0.000472	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—CA2—esophageal cancer	5.7e-05	0.00047	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—FBXW7—esophageal cancer	5.63e-05	0.000464	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—CTNNA1—esophageal cancer	5.52e-05	0.000455	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—CXCL2—esophageal cancer	5.49e-05	0.000452	CbGpPWpGaD
Naltrexone—ABCB1—Integrated Pancreatic Cancer Pathway—CCND1—esophageal cancer	5.43e-05	0.000448	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—CYP1B1—esophageal cancer	5.41e-05	0.000446	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—PLCE1—esophageal cancer	5.3e-05	0.000437	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—ADH7—esophageal cancer	5.3e-05	0.000437	CbGpPWpGaD
Naltrexone—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN1A—esophageal cancer	5.26e-05	0.000433	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—TGFBR2—esophageal cancer	5.19e-05	0.000428	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—NOTCH2—esophageal cancer	5.13e-05	0.000423	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—PSME1—esophageal cancer	5.13e-05	0.000423	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—PSME2—esophageal cancer	5.13e-05	0.000423	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—ANXA1—esophageal cancer	5.1e-05	0.000421	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—CYP19A1—esophageal cancer	5.09e-05	0.000419	CbGpPWpGaD
Naltrexone—ABCB1—Integrated Pancreatic Cancer Pathway—EP300—esophageal cancer	5e-05	0.000412	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—SST—esophageal cancer	4.96e-05	0.000409	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—SMAD4—esophageal cancer	4.92e-05	0.000405	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—GHRL—esophageal cancer	4.84e-05	0.000399	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—NOTCH3—esophageal cancer	4.84e-05	0.000399	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—FBXW7—esophageal cancer	4.76e-05	0.000392	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—ADH1B—esophageal cancer	4.65e-05	0.000383	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—HMOX1—esophageal cancer	4.64e-05	0.000383	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—TGFBR2—esophageal cancer	4.55e-05	0.000375	CbGpPWpGaD
Naltrexone—ABCB1—Transmembrane transport of small molecules—HMOX1—esophageal cancer	4.55e-05	0.000375	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—ABCB1—esophageal cancer	4.46e-05	0.000367	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—TYMP—esophageal cancer	4.44e-05	0.000366	CbGpPWpGaD
Naltrexone—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—esophageal cancer	4.36e-05	0.000359	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—NOTCH2—esophageal cancer	4.34e-05	0.000358	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—CYP26A1—esophageal cancer	4.32e-05	0.000356	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—SMAD4—esophageal cancer	4.31e-05	0.000355	CbGpPWpGaD
Naltrexone—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—esophageal cancer	4.26e-05	0.000351	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—ALOX15—esophageal cancer	4.21e-05	0.000347	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—HIF1A—esophageal cancer	4.02e-05	0.000332	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—GSTO1—esophageal cancer	4.02e-05	0.000331	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—TPI1—esophageal cancer	4.02e-05	0.000331	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—ALDOB—esophageal cancer	3.85e-05	0.000317	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—TGFBR2—esophageal cancer	3.85e-05	0.000317	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—KDR—esophageal cancer	3.85e-05	0.000317	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—GAPDH—esophageal cancer	3.71e-05	0.000306	CbGpPWpGaD
Naltrexone—ABCB1—Integrated Pancreatic Cancer Pathway—PIK3CA—esophageal cancer	3.7e-05	0.000305	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—CRABP1—esophageal cancer	3.67e-05	0.000303	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—SMAD4—esophageal cancer	3.64e-05	0.0003	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—NOTCH1—esophageal cancer	3.62e-05	0.000299	CbGpPWpGaD
Naltrexone—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—esophageal cancer	3.58e-05	0.000295	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—HIF1A—esophageal cancer	3.53e-05	0.000291	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—GNG7—esophageal cancer	3.49e-05	0.000288	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—KDR—esophageal cancer	3.37e-05	0.000278	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—CREBBP—esophageal cancer	3.29e-05	0.000271	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—ALDH2—esophageal cancer	3.27e-05	0.00027	CbGpPWpGaD
Naltrexone—OPRD1—Signaling by GPCR—EGFR—esophageal cancer	3.23e-05	0.000266	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—NOTCH1—esophageal cancer	3.18e-05	0.000262	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—GSTT1—esophageal cancer	3.11e-05	0.000257	CbGpPWpGaD
Naltrexone—OPRD1—GPCR downstream signaling—PIK3CA—esophageal cancer	3.09e-05	0.000254	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—CYP2A6—esophageal cancer	3.08e-05	0.000254	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—HIF1A—esophageal cancer	2.98e-05	0.000246	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—CREBBP—esophageal cancer	2.98e-05	0.000245	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—NOS3—esophageal cancer	2.94e-05	0.000242	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—ENO1—esophageal cancer	2.92e-05	0.000241	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—PTGS1—esophageal cancer	2.92e-05	0.000241	CbGpPWpGaD
Naltrexone—ABCB1—Transmembrane transport of small molecules—CREBBP—esophageal cancer	2.92e-05	0.00024	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—CREBBP—esophageal cancer	2.88e-05	0.000237	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—PSME1—esophageal cancer	2.88e-05	0.000237	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—PSME2—esophageal cancer	2.88e-05	0.000237	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—KDR—esophageal cancer	2.85e-05	0.000235	CbGpPWpGaD
Naltrexone—OPRK1—Signaling by GPCR—EGFR—esophageal cancer	2.83e-05	0.000233	CbGpPWpGaD
Naltrexone—OPRD1—Signaling by GPCR—PIK3CA—esophageal cancer	2.8e-05	0.000231	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—ERBB2—esophageal cancer	2.75e-05	0.000227	CbGpPWpGaD
Naltrexone—OPRK1—GPCR downstream signaling—PIK3CA—esophageal cancer	2.71e-05	0.000223	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—NOTCH1—esophageal cancer	2.69e-05	0.000221	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—NOS3—esophageal cancer	2.67e-05	0.00022	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—NOS3—esophageal cancer	2.58e-05	0.000213	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—CYP1B1—esophageal cancer	2.48e-05	0.000205	CbGpPWpGaD
Naltrexone—OPRK1—Signaling by GPCR—PIK3CA—esophageal cancer	2.46e-05	0.000203	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—PTGS2—esophageal cancer	2.44e-05	0.000201	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—CREBBP—esophageal cancer	2.43e-05	0.000201	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—CCND1—esophageal cancer	2.43e-05	0.0002	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—ERBB2—esophageal cancer	2.41e-05	0.000199	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—EGFR—esophageal cancer	2.39e-05	0.000197	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—CDKN1A—esophageal cancer	2.35e-05	0.000194	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—CYP19A1—esophageal cancer	2.33e-05	0.000192	CbGpPWpGaD
Naltrexone—OPRM1—GPCR downstream signaling—PIK3CA—esophageal cancer	2.29e-05	0.000188	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—EP300—esophageal cancer	2.24e-05	0.000184	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—NOS3—esophageal cancer	2.18e-05	0.00018	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—CCND1—esophageal cancer	2.13e-05	0.000176	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—HMOX1—esophageal cancer	2.13e-05	0.000176	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—PIK3CA—esophageal cancer	2.08e-05	0.000171	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—CDKN1A—esophageal cancer	2.06e-05	0.00017	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—ERBB2—esophageal cancer	2.04e-05	0.000168	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—EP300—esophageal cancer	2.03e-05	0.000167	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—EP300—esophageal cancer	1.96e-05	0.000162	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—MYC—esophageal cancer	1.95e-05	0.000161	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—EGFR—esophageal cancer	1.91e-05	0.000157	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—CCND1—esophageal cancer	1.8e-05	0.000148	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—CDKN1A—esophageal cancer	1.74e-05	0.000144	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—MYC—esophageal cancer	1.71e-05	0.000141	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—EGFR—esophageal cancer	1.67e-05	0.000138	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—EP300—esophageal cancer	1.66e-05	0.000137	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—PIK3CA—esophageal cancer	1.66e-05	0.000136	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—TP53—esophageal cancer	1.6e-05	0.000132	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—PIK3CA—esophageal cancer	1.5e-05	0.000124	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—PIK3CA—esophageal cancer	1.45e-05	0.00012	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—MYC—esophageal cancer	1.44e-05	0.000119	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—EGFR—esophageal cancer	1.41e-05	0.000116	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—TP53—esophageal cancer	1.4e-05	0.000116	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—CREBBP—esophageal cancer	1.37e-05	0.000113	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—PIK3CA—esophageal cancer	1.23e-05	0.000101	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—NOS3—esophageal cancer	1.22e-05	0.000101	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—TP53—esophageal cancer	1.19e-05	9.78e-05	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—PTGS2—esophageal cancer	1.12e-05	9.22e-05	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—EP300—esophageal cancer	9.3e-06	7.67e-05	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—PIK3CA—esophageal cancer	6.88e-06	5.67e-05	CbGpPWpGaD
